Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1653 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| mRNA-1653, Adult participants | EXPERIMENTAL | Participants will receive 1 of 2 doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57. |
| mRNA-1653 Pediatric participants | EXPERIMENTAL | Participants will receive 1 of 2 possible doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57. |
| Placebo, Adult participants | PLACEBO_COMPARATOR | Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57. |
| Placebo, Pediatric participants | PLACEBO_COMPARATOR | Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57. |
| mRNA-1653 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| mRNA-1653 | BIOLOGICAL | Sterile liquid for injection |
| Placebo | BIOLOGICAL | Sterile liquid for injection |
Key Inclusion Criteria: * Adults 18 to 49 years of age and children 12 to 59 months of age at the time of consent who, in the opinion of the Investigator, are in good health based on review of medical history and screening physical examination * Adult participant or parent(s)/legal guardian(s) has ...
mRNA-1653 is an investigational vaccine developed by Moderna, Inc. (ticker MRNA) that is designed to protect against human metapneumovirus and human parainfluenza infection. It is an mRNA-based vaccine candidate and has been studied in Phase 1 clinical trials in healthy adults and in children with serologic evidence of prior exposure.
mRNA-1653 is being developed for the prevention of human metapneumovirus and human parainfluenza infection, two respiratory viral illnesses. It is a vaccine candidate rather than a treatment, and it has been evaluated in Phase 1 studies in healthy adults and in children aged 12 to 59 months with serologic evidence of prior exposure.
mRNA-1653 is developed by Moderna, Inc., which trades under the ticker MRNA. Moderna is the sponsor of the clinical program for this combined human metapneumovirus and parainfluenza virus type 3 vaccine candidate.
mRNA-1653 is in Phase 1 clinical development. It is an investigational vaccine candidate and has not been approved by the FDA. Two Phase 1 trials have been conducted, and both are listed as completed, with no active trials currently reported for this program.
mRNA-1653 has been studied in two completed Phase 1 trials. NCT03392389 evaluated safety, reactogenicity, and immunogenicity in healthy adults and enrolled 124 participants. NCT04144348 evaluated safety and immunogenicity in healthy adults and in children 12 to 59 months of age with serologic evidence of prior exposure, enrolling 51 participants. Both trials were conducted in the United States.